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Abstract 
Objective: The purposes of this project were to quantify the cells expressing the mesenchymal stem cell (MSC) 
marker CD271 in synovial membranes from human osteoarthritic (OA) and healthy joints, and to determine if those 
CD271 cells were involved in spontaneous human cartilage repair and were beneficial for the repair of human 
articular cartilage defects. 
Methods: The coexpression of CD44/CD271, CD90/CD271, and CD105/CD271 antigens was determined by 
immunofluorescence in OA and healthy synovial membranes and during spontaneous cartilage repair. Isolated 
MSCs from the bone marrow of four OA patients (mean age: 64 years) were magnetically separated into MSC 
CD271+ and MSC CD271 subsets. The separated cell subsets were then implanted into 2 mm focal defects of 
articular cartilage. These implants were cultured in chondrogenic differentiation medium supplemented with 
recombinant human transforming growth factor-beta3 for 8 weeks. The repair tissues were analyzed by 
histochemistry (hematoxylin–eosin and safranin O) and immunohistochemistry for collage types I and II. 
Results: Cells expressing the CD271 antigen were diffusely distributed in OA synovial membranes and localized in 
the subintimal zone in healthy synovial membranes. The number of cells expressing MSC markers was higher in 
OA synovial membranes than in synovia from healthy joints, corresponding to the highest level of coexpression of 
CD90/CD271 antigens (9.8% vs. 2.6%). Spontaneous repair tissue showed more cells expressing the CD271 
antigen (9.9% ± 4.0%). The highest levels of expression were found to be associated with CD44; 64% of positive 
CD271 cells coexpressed the CD44 antigen. In both implant cell types, the repair tissue morphology resembled 
articular cartilage, having an extracellular matrix with a hyaline aspect and numerous lacunae containing  cells, and 
was immunopositive for collagen types I and II. Statistical analyses of the repair tissue demonstrated that the 
implantation of MSC CD271+ provided such benefits as a greater filling of the chondral defect and better 
integration between the repair tissue and native cartilage. Safranin O staining of repair tissue was negative in 
implants of MSC CD271- but more positive in implants with MSC CD271+. The overall histologic score for 
CD271 implants was 9.5 ± 0.89 and 12.19 ± 1.01 for CD271+ implants. 
Conclusions: Synovial membranes from OA patients contain more cells expressing CD271 antigen than those from 
healthy joints, and spontaneous cartilage repair tissue contains cells positive for CD271 antigen. These data suggest 
the involvement of CD271 antigen in spontaneous cartilage repair and indicate that the cell subset MSC CD271+ 
provides higher quality chondral repair than the CD271 subset. 
Introduction  
Mesenchymal stem cells (MSCs) are multipotent cells that have the capacity to differentiate into 
various mesodermal tissues, including bone, cartilage, and adipose tissue.
1
 Because there is no specific 
marker for MSCs, these cells are characterized according to their plastic adherence, fibroblastic 
morphology,
2
 and the presence of surface markers (e.g., CD44, CD54, CD71, CD90, and CD166) or 
their absence (e.g., CD14, CD34, and CD45).
3
  
MSCs have been recently identified in human articular cartilage from patients with osteoarthritis 
(OA).
4
 These progenitor cells have been implicated in the process of cartilage repair, although their role 
in the pathogenesis of OA is incompletely understood.
5,6
 Further, MSCs in synovial fluid were more 
numerous in patients with OA than in healthy individuals,
7
 but a detailed quantification of the MSCs in 
synovial membranes has not been performed.  
In vitro
1,8,9
 and in vivo
10
 studies of clonally derived MSCs demonstrated that the MSC population 
consists of subsets that have different expression of markers and different capacities for cellular 
differentiation. These results suggest that a specific cell population may be advantageous for tissue 
repair. An immunoisolation method has been used to obtain MSC populations positive for specific 
markers, such as STRO-1,
10,11
 CD105,
12,13
 and CD271, also known as low affinity nerve growth factor 
receptor.
14,15
 Recent studies have indicated that the population of MSCs resulting from selection for 
cells expressing CD271 showed a greater clonogenic potential and a higher capacity for adipogenic and 
osteogenic differentiation.
14,15
  
In the present study, we analyzed the differences in the incidence of CD271 cells from synovial 
membranes from OA patients and healthy joints. We also determined whether CD271+ cells are 
involved in spontaneous cartilage repair. We observed that CD271+ cells are more abundant in OA 
patients and are present in the spontaneous repair tissue of OA cartilage. To evaluate whether CD271+ 
cells are implicated in articular cartilage repair and whether they are able to reach damaged cartilage 
through the vascular system, we determined the capacity of bone marrow (BM)-derived CD271+ cells 
to repair articular cartilage defects.  
Materials and Methods  
Harvest of synovial tissues and articular cartilage  
Synovia from 20 OA patients (mean age: 65 years) and 6 patients with healthy joints (mean age: 47 
years) were obtained aseptically during hip joint prosthetic replacement surgery. The synovial 
membranes were kept in sterile Eagle’s minimum essential medium (Cambrex) supplemented with 
10,000 IU/mL penicillin and 10,000 µg/mL streptomycin. Synovial membrane samples from each 
patient were also immersed in isopentane/liquid N2 and held at -80ºC until processed for 
immunostaining.  
Normal articular cartilage from donors with no history of joint disease was provided by the Tissue 
Bank and the Autopsy Service at A Coruña Hospital. All tissues were obtained from femoral heads, 
sliced full thickness excluding mineralized cartilage and subchondral bone, and placed in Dulbecco’s 
modified Eagle’s medium (DMEM) (Lonza) with 20% fetal bovine serum (FBS) (Gibco) and 10,000 
IU/mL penicillin and 10,000 µg/mL streptomycin.  
This study was approved by the local ethics committee and informed consent was obtained from all 
donors.  
Immunofluorescence of synovial membranes and articular cartilage  
Frozen sections (four healthy and four OA synovial membrane tissue samples) of 4 µm were cut, 
mounted on Superfrost Plus microscope slides, and fixed in acetone at 4ºC for 10 min. Monoclonal 
antibodies against CD44, CD90, CD105, and CD271 were used for immunofluorescent assays 
(Supplementary Table S1; Supplementary Data are available online at www.liebertonline.com/tea).  
For double immunostaining for CD44/CD271 and CD90/ CD271, sections were first exposed to 
mouse anti-human CD44 antibody (1:100) or mouse anti-human CD90 antibody (1:400), then incubated 
with rabbit anti-mouse fluorescein isothiocyanate (FITC)-labeled antibodies (1:10). For CD105/CD271 
double immunostaining, the sections were first exposed to monoclonal anti-human CD105-FITC 
antibody (1:10). The sections were then exposed to mouse anti-human CD271 antibody (1:1,000) and 
incubated with goat anti-mouse R-phycoerythrin (PE)-labeled antibodies (1:20). Nuclei were 
counterstained with DAPI (100 ng/mL, 20 min). Immunofluorescence was green (FITC) for CD44, 
CD90, and CD105, and red (PE) for CD271.  
Immunofluorescence incubations were for 30 min at room temperature in the dark. Between 
incubations, the sections were washed in phosphate-buffered saline. Negative staining controls were 
obtained by omitting the primary antibody and incubating with the secondary antibodies conjugated 
with FITC or R-PE. The sections were mounted in Glycergel (Dako Corporation).  
  
Isolation and culture of BM-derived mesenchymal cells  
BM samples (N=4) were obtained from hip OA patients (mean age: 64.3 years; age range: 35–82 
years). Informed consent was obtained from each donor according to the guidelines of the local ethics 
committee.  
BM-derived mesenchymal cells were extracted by washing the BMwith 50mL of DMEM, 10% FBS 
with a 1,1mm x 25mm gauge needle (BD Microbalance
TM
 3) and a 20mL syringe (Kendall Monoject 
Syringe). The resulting cell suspension was filtered through a sterile 40 µm filter and centrifuged at 300 
g for 8 min. Then, 1 x 10
5
 cells were plated in a culture flask. The nucleated cells were cultured in 
DMEM supplemented with 20% FBS and penicillin/streptomycin (10,000 IU/mL) (both from Gibco 
BRL, Life Technologies, Barcelona, Spain) in a humidified 5% CO2 atmosphere at 37ºC. After 48 h, 
nonadherent cells were removed.  
When the BM-derived cells became confluent, they were sub-cultured using trypsin–
ethylenediamine tetraacetic acid treatment (Sigma-Aldrich). To reduce contamination by fibroblasts, the 
resultant cell suspension was subjected to a preplating technique.
16
 The basis for this technique is that 
MSCs require more time to attach to the culture dish than fibroblasts. Therefore, cells that had not 
adhered within 20 min were resuspended in fresh medium and reseeded. All experiments in this study 
were performed with cells from the second passage. Cells were counted and assessed for viability using 
Trypan blue 0.4% (Sigma) dye exclusion.  
Immunomagnetic isolation of BM-derived mesenchymal cells CD271 and CD271+  
The cell suspension (N=4) was washed with magnetic cell sorting (MACS) buffer containing 
phosphate-buffered saline at pH 7.2, 0.5% bovine serum albumin (BSA), and 2mM ethylenediamine 
tetraacetic acid and stored at 4ºC. The cells were then resuspended in MACS buffer at a concentration 
of 107 cells per 80 mL and incubated first with CD271-APC for 10 min at 4ºC and then with Anti-(low 
affinity nerve growth factor receptor)-APC Microbeads for 15 min at 4ºC. The resultant cell suspension 
was then loaded onto a MiniMACS Separator column (Miltenyi Biotec) and placed in the magnetic field 
of a MACS Separator, and the column was washed with MACS buffer. The magnetically labeled 
CD271+ cells were retained on the column, whereas the unlabeled cells run through; this cell fraction 
was depleted of CD271+ cells. After removal of the column from the magnetic field, the magnetically 
retained CD271+ cells were eluted as the positively selected cell fraction. The resulting CD271+ and 
CD271 cells were centrifuged at 300 g for 8 min. Then, 1 x 105 cells were plated in a culture flask. 
These nucleated cells were cultured in DMEM with 20% FBS and penicillin/streptomycin in a 
humidified 5% CO2 atmosphere at 37ºC.  
BM-derived mesenchymal cells characterization by flow cytometry  
The phenotypic characterization of the BM-derived cells (N=4) was achieved using the 
formaldehyde-saponin method. Cell suspensions from freshly isolated synovial membranes and from 
the second passage were incubated for 1 h at 4ºC with mouse anti-human monoclonal antibodies 
conjugated with fluorochromes (Supplementary Table S1). A goat anti-mouse IgG FITC-conjugate 
(Southern Biotechnology Associates, Inc.) was used as a secondary antibody when necessary. A 
minimum of 10,000 cell-events per assay were analyzed on a FACsCalibur cytometer (Becton 
Dickinson) and the resulting data were processed using CellQuest software (Becton Dickinson).  
Statistical analysis was performed using the Mann–Whitney U-test. The results are expressed as 
percentage of marker cells (mean ± standard deviation). Differences are considered statistically 
significant if p<0.05.  
Chondral defects and implants of BM-derived mesenchymal cells CD271 and CD271+  
In full-thickness cartilage slices, on the surface, were drilled chondral defects (2 mm diameter and 
2–3 mm deeper). Then were made cylinder (6mm diameter) (Biopsy Punch Stiefel) with the chondral 
defects inside. Chondrogenic medium (Lonza) alone was used for the control group, whereas 2 x 10
5
 
CD271+ or CD271 cell subsets were seeded over the chondral defect produced. Samples were then 
transferred to 96-well plates with 150 µL of chondrogenic medium and incubated for 4 and 8 weeks at 
37ºC in a humidified 5% CO2 atmosphere, after which the samples were fixed in 4% paraformaldehyde 
and embedded in paraffin. The repair tissues were then analyzed by histochemical staining with 
hematoxylin-eosin and safranin O or by immunohistochemical methods for collagen types I and II.  
Immunoperoxidase staining of paraffin tissue sections  
The implants were fixed in 4% paraformaldehyde and paraffin-embedded, and then 4-µm-thick 
sections were placed on Superfrost Plus slides (Menzel-Glaser) and incubated with monoclonal 
antibodies (Supplementary Table S1). Some sections were enzymatically pretreated to facilitate 
exposure of various epitopes (Supplementary Table S1). The peroxidase/DAB ChemMate
TM
 DAKO 
EnVision
TM
 detection kit (Dako Cytomation) was employed to detect the antigen–antibody reactions. 
Negative staining controls were created by omission of the primary or secondary antibodies.  
Morphometric analysis  
For each synovium sample, five consecutive sections were examined using an Olympus BX61 
microscope connected to a digital camera (Olympus DP70). Images of four fields were acquired for 
each section. At least 2 x 10
3
 cells were counted for each staining experiment. Cells with DAPI nuclear 
staining and cells with single (CD271) or double (CD44/ CD271; CD90/CD271 or CD105/CD271) 
immunostaining were independently quantified and the respective percentages calculated.  
The results represent different simultaneous analyses of two antigens. In each sample, the 
percentage of cells positive for each marker was calculated by dividing the number of cells expressing 
the marker by the number of cells stained with DAPI; the percentage of cells simultaneously expressing 
two markers was calculated by dividing the number of cells positive for two markers by the number of 
cells stained with DAPI. The results are expressed as mean % ± standard deviation.  
The International Cartilage Repair Society scoring system 
17
 was used for the macroscopic 
evaluation of cartilage repair (Table 1). The results are expressed as mean ± standard deviation. Three 
different experiments with six samples at each time point were carried out, so there were 18 samples at 
each time point. The groups were compared using the two-tailed Mann–Whitney U-test or the Student’s 
t-test. Differences were considered significant when p<0.05. 
Table 1. International Cartilage Repair Society Macroscopic Evaluation of Cartilage Repair After 8 Weeks of Culture 
International Cartilage Repair Society parameters CD271+ CD271 
   
Degree of defect repair   
(in level with surrounding cartilage, 4; 75% repair of defect depth, 3; 50% repair 
of defect depth, 2; 25% repair of defect depth, 1; 0% repair of defect depth, 0) 
2.33 ± 0.84 (n=6) 1.00 ± 0 (n=9) 
Integration to border zone   
(complete integration with surrounding cartilage, 4; demarcating border <1 mm, 
3; 3/4 th of graft integrated, 1/4 th with a notable border >1mm width, 2; 1/2 of 
graft integrated with surrounding cartilage, 1/2 with a notable border >1mm, 1; 
from no contact to 1/4 th of graft integrated with surrounding cartilage, 0) 
3.50 ± 0.55 (n=6) 2.33 ± 0.50 (n=9) 
Macroscopic appearance   
(intact smooth surface, 4; fibrillated surface, 3; small, scattered fissures or 
cracks, 2; several, small or few but large fissures, 1; total degeneration of 
grafted area, 0) 
3.30 ± 0.46 (n=30) 2.29 ± 0.37 (n=26) 
Overall repair assessment   
(Grade I: normal, 12; Grade II: nearly normal, 11–8; Grade III: abnormal, 7–4; 
Grade IV: severely abnormal, 3–1) 
10.02 ± 0.81 (n=41) 7.48 ± 0.63 (n=29) 
Total  19,16 ± 2,65 13,10 ± 1,50 
   
 
The results are expressed as the mean_standard deviation. 
Statistical analysis  
All statistical analyses were performed using SPSS 16.0 software for Windows; p-values<0.05 were 
considered statistically significant.   
Results  
Topographic location and quantification of cells expressing CD271 antigen in healthy and OA synovial 
membranes  
There was an important difference in the site of cells expressing the MSC marker CD271 in OA and 
healthy synovial membranes. In healthy specimens, cells expressing CD271 were located in the intimal 
lining (Fig. 1). In OA specimens, the distribution of CD271+ cells was more diffuse and they were 
located deeper than the subintimal layer, around veins in the perivascular matrix.  
 
 
 
FIG. 1. Cells expressing the CD271 antigen with CD44, CD90, and CD105 antigens in 
synovial membranes shown by immunofluorescence. (a, b) Hematoxylin–eosin stain. (c–h) 
Monoclonal antibodies were used for the immunofluorescent detection of cells expressing 
CD271 alone or simultaneously with CD44, CD90, or CD105. CD44, CD90, or CD105 
immunoreactivity appears green, whereas CD271 immunoreactivity appears red. (c, d) CD44 
and CD271 double immunofluorescence of (a) healthy and (b) osteoarthritic (OA) synovial 
membranes. (e, f ) CD90 and CD271 double immunofluorescence of (a) healthy and (b) OA 
synovial membranes. (g, h) CD105 and CD271 double immunofluorescence of (a) healthy and 
(b) OA synovial membranes. H, healthy synovial membranes. Magnification: (a, b) x 100; (c–
h) x 400. Color images available online at www.liebertonline .com/tea.  
  
Cells expressing the mesenchymal markers CD44, CD90, CD105, and CD271 were quantified using 
double immunofluorescent staining of frozen tissues, simultaneously analyzing two antigens. The 
percentages of cells expressing MSC markers were higher in OA than in healthy synovial membranes 
(Fig. 2). However, only the simultaneous expression of CD44/CD271 and CD90/CD271 antigens was 
significantly higher in OA than in healthy synovial membranes (1.09% vs. 2.2% for CD44/CD271, and 
2.1% vs. 8.1% for CD90/CD271) ( p<0.05 for both sets of data).  
 
 
 
FIG. 2. Quantification of cells expressing mesenchymal 
stem cell (MSC) markers in synovial membranes using 
immunofluorescence. Graph showing percentages of 
synovial membrane cells simultaneously expressing CD44 
and CD271, CD90 and CD271, and CD105 and CD271. 
Results are expressed as the mean ± standard deviation. 
*p<0.05.  
The association of expression of the CD271 antigen with the expression of CD44, CD90, and 
CD105 antigens showed differences among these markers and between healthy and OA synovial 
membranes. The level of association of the expression of the CD271 antigen with the CD44 antigen 
(Fig. 3a) was moderate in healthy synovial membranes (56.8% ± 18.2% of CD271+ cells were also 
positive for the CD44 antigen), but this level was higher in OA synovia, where 88.0%_12.2% of 
CD271þ cells were positive for CD44. On the other hand, the expression of CD271 antigen was 
associated with the expression of the CD90 antigen in both healthy and OA synovial membranes (Fig. 
3a). More than 80% of CD271+ cells in healthy and OA synovial membranes coexpressed the CD90 
antigen. The expression of the CD271 antigen showed a low level of association with the expression of 
the CD105 antigen in both healthy and OA synovial membranes (Fig. 3a). Only 31.2% ± 23.6% of 
CD271+ cells in healthy and 26.9% ± 29.7% in OA synovial membranes were also positive for the 
CD105 antigen.  
The expression of the CD44 antigen was strongly associated with that of the CD271 antigen (Fig. 
3b); 81.8% ± 11.1% of CD44+ cells in healthy and 68.7% ± 2.7% in OA synovial membranes were 
CD44/CD271. The association of expression of the CD90 antigen with the CD271 antigen was 
significantly different (p<0.05) between healthy and OA synovial membranes (Fig. 3c). In healthy 
synovial membranes, 37.8% ± 12.1% of CD90+ cells also expressed CD271, whereas in OA synovium, 
82.6% ± 13.2% of CD90+ cells were also CD271+. The expression of the CD105 and CD271 antigens 
showed a lower level of association (Fig. 3d); 38.5% ± 22.7% of CD105+ cells in healthy and 58.3% ± 
41.7% in OA synovial membranes were also positive for the CD271 antigen.  
To summarize, the expression of the CD271 antigen was strongly associated with the expression of 
CD90 in both healthy and OA synovial membranes and with the expression of the CD44 antigen in OA 
synovial membranes. The expression of the CD271 antigen, however, was less strongly associated with 
the expression of the CD105 antigen in both healthy and OA synovial membranes.  
  
 
 
 
FIG. 3. Association of CD271 antigen expression with the expression of 
CD44, CD90, and CD105 antigens in synovial membranes. Each column 
represents the percentage of cells positive for one antigen also positive for 
another antigen (black solid box) in healthy (H) and OA synovial 
membranes. (a) The percentage of CD271+ cells expressing CD44, CD90, 
and CD105 antigens. (b) The percentage of CD44+ cells expressing the 
CD271 antigen. (c) The percentage of CD90+ cells expressing the CD271 
antigen. (d) The percentage of CD105+ cells expressing the CD271 antigen.  
Study of MSC markers in spontaneous repair tissue  
The analysis of tissues localized in OA-damaged cartilage (spontaneous repair tissue) (Fig. 4a–d) 
showed a high percentage of cells expressing CD271 (9.9% ± 4.0%) (Fig. 4e). Most CD271+ cells were 
found to be associated with CD44; 64% of CD271+ cells coexpressed the CD44 antigen (Fig. 4e). The 
coexpression of CD271 with CD90 was low; only 8% of CD271+ cells were also CD90+. The CD105 
antigen was not present in spontaneous repair tissue.  
  
 
 
 
FIG. 4. Cells expressing CD44 and CD271 antigens in spontaneous repair tissue of OA 
articular cartilage. Monoclonal antibodies were used in frozen sections for the 
immunofluorescence detection of CD44 and CD271. (a) OA articular cartilage repair tissue 
stained with hematoxylin–eosin. (b) Detection of CD44 (green) and CD271 (red) antigens 
(panels c and d are higher magnifications of insets in panel b). (c) Cells expressing CD44 
antigen. (d) Cells coexpressing CD44 and CD271 antigens. Scale bars: (a, b) 50 µm; (c, d) 20 
µm. (e) Graph showing the percentage of cells in spontaneous repair tissue of OA articular 
cartilage that express CD271, as well as cells simultaneously expressing CD44 and CD271, 
CD90 and CD271, or CD105 and CD271. The results are expressed as the mean ± standard 
deviation. Color images available online at www.liebertonline.com/tea.  
In vitro repair of chondral defects with BM-derived CD271+ and CD271 cells  
The phenotypic characterization of CD271 and CD271+ BM-derived mesenchymal cells (Fig. 5) 
demonstrated that both cellular populations are negative for the hematopoietic antigens CD34 and CD45 
and had similar positive percentages for the antigens CD44, CD73, and CD90. These populations 
showed substantial differences only in the positive percentages for CD29 (CD271: 74.26% ± 22.87%; 
CD271+: 56.58% ± 32.31%), CD105 (CD271: 41.22% ± 32.91%; CD271+ 20.81% ± 24.82%), and 
CD166 (CD271: 52% ± 31.68%; CD271+: 44.05% ± 36.65%). Both cell populations have adipogenic, 
osteogenic, and chondrogenic capacity (Fig. 6).  
  
 
 
 
FIG. 5. The phenotypic characterization of CD271 and CD271+ bone marrow-derived 
mesenchymal cells. Cells were harvested, centrifuged, washed, and counted before cell 
phenotype characterization using the formaldehyde-saponine method. The antibodies listed in 
Supplementary Table S1 were used for this procedure. Predetermined optimal amounts of anti-
mouse or anti-human monoclonal antibodies were added directly to 2 x 105 cells for 1 h at 4ºC. 
A minimum of 10,000 cell events per assay were analyzed with a FACsCalibur flow 
cytometer. This figure shows representative histograms of multipotential MSCs by FACs. The 
purple line signifies the specific antibody, whereas the green line represents the isotype 
control. Color images available online at www.liebertonline.com/tea.  
After creation of the chondral defect described above, native cartilage discs showed depletion of 
proteoglycans in the cartilage zone located at the edge of the injury. This depletion occurred in 
cartilages of both the control and CD271+ or CD271 cell implant groups; the deterioration was more 
evident during longer culture periods. The chondral defect affected the superficial and transitional zones 
of the cartilage. The surface of the defects was irregular, with numerous small cavities distributed along 
the lesion edge.  
  
 
 
 
FIG. 6. Chondrogenic, adipogenic, and osteogenic capacities of CD 271+ and CD 271. 
Adipogenesis (a, b). The presence of adipocytes was assessed by detection of lipidic drops 
with oil red stain. Osteogenesis (c, d). Scale bar value is 500 µm. The presence of calcium 
deposits was demonstrated by alizarin red stain. Chondrogenesis (e–h). Scale bar value is 200 
µm. It was assessed by incubation of cells in micropellet culture with chondrogenic 
differentiation medium and transforming growth factor-b3; micromasses were stained for 
proteoglycans with toluidine blue and immunodetection of type II collagen. Color images 
available online at www.liebertonline .com/tea.  
No repair was observable in chondral defects receiving only chondrogenic medium (control group). 
In contrast, chondral defects receiving MSC CD271+ or CD271 (implant groups) showed abundant 
repair tissue after 8 weeks of culture (Fig. 7). In both implant groups, the repair tissue morphology 
showed an extracellular matrix with a hyaline aspect and numerous lacunae containing round cells, 
resembling articular cartilage. The cell density was higher in repair tissue than in the native cartilage 
and in both types of implants the expression of collagen types I and II was observed.  
Statistical analyses of the repair tissue at 8 weeks of culture showed significant differences in tissue 
morphology, filling of the defect, cellularity, integration of newly formed tissue, cell morphology, and 
matrix staining between implant groups (Table 1). The degree of defect repair was less in the implants 
with MSC CD271 (1.00% ± 0%) than in those with MSC CD271+ (2.33 ± 0.84). Safranin O stain of 
the repair tissue was negative in the implants with MSC CD271 and moderately positive in implants 
with MSC CD271+. The integration between repair tissue and the adjacent normal cartilage was of 
better quality in the MSC CD271+ implants. The overall histologic score for CD271 implants was 
13.10 ± 1.50 and 19.16 ± 2.65 for CD271+ implants.  
 
 
 
FIG. 7. In vitro chondral defect repair. Repair of chondral defects with implants of MSC 
CD271 (a, c, e, g) and MSC CD271+ (b, d, f, h). In both groups of implants, the repair tissue 
showed extracellular matrix with a hyaline aspect and numerous lacunae containing rounded 
cells (a, b, arrows) and the expression of collagen type I (c, d) and type II (e, f ). Safranin O 
stain of the repair tissue was negative in the MSC CD271 implants and moderately positive 
in MSC CD271+ implants (g, h). Color images available online at www.liebertonline .com/tea.  
Discussion  
This study demonstrates for the first time that human synovial tissues and the spontaneous repair 
tissue of OA articular cartilage contain cells expressing the CD271 antigen. The expression of CD271 
antigen in MSCs has been previously described in some human tissues, including BM,
14,15,18,19
 the joint 
fat pad,
20
 and fetal membranes.
15
 CD271 mRNA has been reported in BMMSCs.
21
 Other research has 
shown that CD271 is a key marker of MSCs in BM and other tissues. The isolation of MSCs positive 
for CD271 using antibodies directed against the CD271 antigen should provide a phenotypically and 
functionally homogeneous cell population
14,22
 with high potentials for clonogenicity and differentiation 
into the multiple lineages of mesenchymal cells.
14,15
 
We observed that the expression of CD271, CD44, and CD90 antigens, but not of CD105 antigen, is 
significantly higher in OA than in healthy synovial tissues. Because these antigens have been identified 
as MSC markers from BM, adipose tissue, and synovial membranes,
23,24
 these results suggest a greater 
presence of MSCs in OA synovia than in healthy synovia.  
  
The expression of the CD271 antigen was highly associated with the expression of CD44 and CD90 
antigens in OA synovial membranes, whereas its association with the expression of the CD105 antigen 
was lower. Further, the phenotypic analysis of the immnuno-selected cell population for the CD271 
antigen showed that only 2.3% of the cells expressed the CD105 antigen. These results suggest that the 
MSC CD271+ subset has unique phenotypic characteristics different from other MSC subsets, such as 
MSC CD105+.  
We found that 64% of the cells in OA articular cartilage spontaneous repair tissue that express the 
CD271 antigen are also positive for CD44, another marker for MSCs.
1
 A recent study found that 
chondrocyte populations sorted for the CD44 marker antigen generate cartilaginous tissue of superior 
quality compared to that of unsorted cells.
25
 These data suggest that CD271 is a marker for MSCs 
implicated in the repair mechanism of damaged cartilage.  
The presence of cells expressing MSC markers in OA cartilage spontaneous repair tissue raises the 
question of the source of these cells. In chondral defects the cells that promote cartilage repair are MSCs 
from the same cartilage
5 
or MSCs from neighboring tissues, such as synovial membranes 
26
 or the fat 
pad.
20
 It seems possible that MSCs from neighboring tissues migrate through the synovial cavity to the 
chondral defect and participate in the process of cartilage repair. Another possibility is that MSCs were 
transported to neighboring tissues through the vascular system, and from there migrate to the damaged 
cartilage. It has been shown that in osteochondral defects BMMSCs are included in a fibrin clot that 
migrates to the lesion and promotes repair tissue.
27
  
We observed an increase in the expression of CD271 in OA synovial membranes and a higher 
expression of CD271 antigen in cells located in OA articular cartilage repair tissue. Curiously, in human 
arthritic synovial fluid, the CD271 antigen was found on the surface of MSCs,
7
 but MSCs in normal 
bovine synovial fluid were negative for CD271.
28
 Taken together, these findings suggest that, in the 
cartilage degenerative process, CD271+ MSCs from BM are activated and mobilized to travel through 
the vascular system. These cells first arrive at the synovial membrane then reach the damaged cartilage.  
To summarize, synovial membranes from OA patients contain more cells expressing CD271 antigen 
than do those from joints with no cartilage damage, and spontaneous cartilage repair tissue contains 
cells positive for CD271 antigen. These findings imply the involvement of CD271+ MSCs in the repair 
mechanism for damaged articular cartilage. To evaluate the possible mobilization of CD271+ cells 
through the vascular system to arrive at damaged cartilage, we determined the capacity of CD271+ cells 
isolated from BM to repair articular cartilage defects in a chondrogenic medium. The repair of chondral 
defects in animal models using MSCs injected into defects closed with periosteum
29
 or embedded in 
collagen gel
30
 indicates that the MSCs can differentiate according to the biological medium in which 
they are grown.  
This is the first in vitro study showing that implants of MSCs expanded in monolayer culture can 
repair focal defects in human articular cartilage. Using a relatively short 8-week culture time, both MSC 
CD271 and MSC CD271+ implants formed repair tissue that showed both cartilaginous (extracellular 
matrix immunopositive for collagen type II with a hyaline aspect and numerous lacunae containing 
rounded cells) and fibrous (immunopositive for collagen type I) characteristics.  
Studies of autologous chondrocyte implants show that, 1 year after implantation, fibrocartilaginous 
morphology regions and hyaline morphology regions are coexistent in the same biopsy regions.
31,32,33
 
Further, the expression of an aggrecanase activity higher than metalloprotease activity
33
 and the 
expression of collagen mRNA indicate the prechondrocytic state (type IIA) and differentiated 
chondrocytes (type IIB) occur in repair tissue.
34,35
 These data suggest that the regeneration of articular 
cartilage probably occurs through turnover and remodeling of an initial fibrocartilaginous matrix using 
enzymatic degradation and synthesis of collagen type II,
33
 and that this process is prolonged over time.
36
  
The quality of repair tissue is limited by the in vitro model. In an animal model, several cell types 
could contribute to the repair of cartilage, such as chondrocytes from native cartilage, implanted 
chondrocytes or stem cells, and stem cells from periosteum, perichondrium, and/or BM.
29,37
 In our in 
vitro model, the cell types are restricted to native cartilage chondrocytes and implanted MSCs. Other 
important limitations are the absence of biochemical signals from surrounding tissues stimulating 
chondrogenesis and differentiation, biomechanical stimuli, and the use of short culture times. The lack 
of data over the long process of regeneration of cartilage and the limitations of our in vitro model may 
explain the coexistence of fibrous and cartilaginous characteristics in the repair tissue.  
Although both implant groups participated in the tissue repair process, the MSC CD271+ implants 
were found to provide improved repair. CD271+ cells achieved more filling of the chondral defect, 
better integration of the repair tissue with the native cartilage, improved regularity of the repair tissue 
surface, and greater chondrocytic morphology of the repair tissue cells. Further, repair tissue after MSC 
CD271+ implants showed moderate staining by safranin O, indicating the presence of proteoglycans. 
  
A factor that can affect the quality of repair tissue is the homogeneity of the MSC CD271+ 
population. In this study, we used an immunomagnetic method of cell isolation to obtain an MSC 
population positive for CD271. This cell population was practically homogenous for CD44 and CD90 
antigens, but only low percentages of cells expressed the CD29 and CD166 antigens. A comparative 
analysis between BM-MSC CD271 (bright) and CD271 (dim) populations as screened by flow 
cytometry showed that only the CD271 (bright) population was positive for established MSC markers 
and contained fibroblast colony forming units.
22
  
For the effective clinical use of MSCs in the treatment of focal cartilage defects, one critical 
investigation will be to determine the optimal population of MSCs for implantation to repair articular 
cartilage damage. Our results suggest that the MSC CD271+ subset promotes the repair of articular 
cartilage defects.  
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